Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
|Videos|May 6, 2022
What to watch for at ACOG 2022, according to past president Eva Chalas, MD
Author(s)Lindsey Carr, Editor
Immediate past president Eva Chalas, MD, discusses the top sessions, events and presentations to watch for at ACOG's annual meeting.
Advertisement
Advertisement
Related to this article
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.
Risa Kagan, MD, on bone health prevention in primary care and why baseline bone density testing should come before age 65.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
What biomarker-guided preeclampsia care could look like
2
Testosterone for women: Global consensus and physiologic dosing
3
Testosterone physiology in women and the long road to approval
4
Testosterone in women: Androgenic adverse events and lab monitoring
5